Global Information
회사소개 | 문의 | 비교리스트

세계의 인슐린 주사기 시장 기회 분석 및 산업 예측(2021-2030년) : 주사기 사이즈(3/10cc 주사기, 1/2cc 주사기, 1cc 주사기, 기타), 질환, 최종사용자별

Insulin Syringes Market by Syringe Size (3/10 cc Syringe, 1/ 2 cc Syringe, 1cc syringe, and Others), Disease, End User : Global Opportunity Analysis and Industry Forecast, 2021-2030

리서치사 Allied Market Research
발행일 2021년 12월 상품코드 1059632
페이지 정보 영문 201 Pages 배송안내 2-3일 (영업일 기준)
가격
US $ 4,125 ₩ 5,256,000 Excel (Data Pack) help
DRM(디지털 저작권 관리 시스템) 장착 Excel 파일로, 1명만 이용할 수 있는 라이선스입니다. 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 Excel파일 라이선스 소유자로 한정됩니다.
US $ 6,168 ₩ 7,859,000 PDF (Single User License + Covid impact) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 6,929 ₩ 8,828,000 PDF (5-user License) help
DRM(디지털 저작권 관리 시스템) 장착 PDF 파일로, 5명까지 이용할 수 있는 라이선스입니다. 인쇄는 5회까지 가능하며 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 10,663 ₩ 13,586,000 PDF (Enterprise User License) help
동일 기업 내의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 인슐린 주사기 시장 기회 분석 및 산업 예측(2021-2030년) : 주사기 사이즈(3/10cc 주사기, 1/2cc 주사기, 1cc 주사기, 기타), 질환, 최종사용자별 Insulin Syringes Market by Syringe Size (3/10 cc Syringe, 1/ 2 cc Syringe, 1cc syringe, and Others), Disease, End User : Global Opportunity Analysis and Industry Forecast, 2021-2030
발행일 : 2021년 12월 페이지 정보 : 영문 201 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 인슐린 주사기 시장 규모는 2020년 15억 6,120만 달러에서 예측기간에는 4.4%의 연평균 복합 성장률(CAGR)로 확대되어 2030년까지 24억 151만 달러 규모로 성장할 것으로 예측됩니다.

고령화 사회의 도래, 세계적인 당뇨병 환자 증가, 인슐린 주사기에 관련된 유리한 정부 정책, 비만 증가, 건강하지 못한 라이프스타일 등의 요인이 시장 성장의 원동력이 되고 있습니다. 한편, 인슐린 주사 대체 방식의 존재, 인슐린의 높은 가격이 시장 성장을 억제하고 있습니다.

세계의 인슐린 주사기(Insulin Syringes) 시장을 조사했으며, 시장의 정의와 개요, 시장 영향요인 분석, 시장 규모 추이와 예측, 주사기 사이즈·질환·최종사용자·지역/주요 국가 등 각종 구분별 분석, 경쟁 환경, 주요 기업 프로파일 등의 정보를 정리하여 전해드립니다.

목차

제1장 서론

제2장 개요

제3장 시장 구도

  • 시장의 정의와 범위
  • 주요 기업의 포지셔닝
  • 시장 형성 요인
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 시장 기회
    • 영향 분석
  • COVID-19의 영향

제4장 인슐린 주사기 시장 : 주사기 사이즈별

  • 개요
  • 3/10cc 시린지(0.3ml)
  • 1/2cc 시린지(0.5ml)
  • 1cc 시린지(1ml)
  • 기타
    • 주요 시장 동향, 성장요인, 기회
    • 시장 규모와 예측
    • 시장 분석 : 국가별

제5장 인슐린 주사기 시장 : 질환별

  • 개요
  • 1형 당뇨병
  • 2형 당뇨병
    • 시장 규모와 예측
    • 시장 분석 : 국가별

제6장 인슐린 주사기 시장 : 최종사용자별

  • 개요
  • 병원&클리닉
  • 재택치료
  • 기타
    • 시장 규모와 예측
    • 시장 분석 : 국가별

제7장 인슐린 주사기 시장 : 지역별

  • 개요
  • 북미
  • 유럽
  • 아시아태평양
  • 라틴아메리카, 중동 및 아프리카
    • 주요 시장 동향과 기회
    • 시장 규모와 예측 : 국가별
    • 시장 규모와 예측 : 주사기 사이즈별
    • 시장 규모와 예측 : 질환별
    • 시장 규모와 예측 : 최종사용자별

제8장 기업 개요

  • Abbott Laboratories
  • Biocon Ltd
  • Becton, Dickinson and Company
  • CARDINAL HEALTH
  • Eli Lily and Company
  • HINDUSTAN SYRINGES AND MEDICAL DEVICES LTD
  • Medline Industries
  • NIPRO MEDICAL CORPORATION
  • NOVO NORDISk
  • TERUMO CORPORATION
LSH 22.03.10

LIST OF TABLES

  • TABLE 01.INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 02.INSULIN SYRINGES MARKET FOR 3/10 CC SYRINGES (0.3 ML), BY REGION, 2020-2030 ($MILLION)
  • TABLE 03.INSULIN SYRINGES MARKET FOR 1/2 CC SYRINGE (0.5 ML), BY REGION, 2020-2030 ($MILLION)
  • TABLE 04.INSULIN SYRINGES MARKET FOR 1CC SYRINGE (1 ML), BY REGION, 2020-2030 ($MILLION)
  • TABLE 05.INSULIN SYRINGES MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 06.INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 07.INSULIN SYRINGES MARKET FOR TYPE-1 DIABETES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 08.INSULIN SYRINGES MARKET FOR TYPE-2 DIABETES, BY REGION, 2020-2030 ($MILLION)
  • TABLE 09.INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 10.INSULIN SYRINGES MARKET FOR HOSPITAL& CLINICS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 11.INSULIN SYRINGES MARKET FOR HOMECARE SETTINGS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 12.INSULIN SYRINGES MARKET FOR OTHERS, BY REGION, 2020-2030 ($MILLION)
  • TABLE 13.INSULIN SYRINGES MARKET, BY REGION, 2020-2030 ($MILLION)
  • TABLE 14.NORTH AMERICA INSULIN SYRINGES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 15.NORTH AMERICA INSULIN SYRINGES MARKET, BYSYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 16.NORTH AMERICA INSULIN SYRINGES MARKET, BYDISEASE, 2020-2030 ($MILLION)
  • TABLE 17.NORTH AMERICA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 18.U.S. INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 19.U.S. INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 20.U.S. INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 21.CANADA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 22.CANADAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 23.CANADA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 24.MEXICO INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 25.MEXICO INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 26.MEXICO INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 27.EUROPE INSULIN SYRINGES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 28.EUROPE INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 29.EUROPE INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 30.EUROPE INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 31.GERMANY INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 32.GERMANY INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 33.GERMANY INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 34.FRANCE INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 35.FRANCEINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 36.FRANCE INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 37.UK INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 38.UKINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 39.UK INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 40.ITALY INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 41.ITALY INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 42.ITALY INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 43.SPAIN INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 44.SPAININSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 45.SPAIN INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 46.REST OF EUROPE INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 47.REST OF EUROPEINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 48.REST OF EUROPE INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 49.ASIA-PACIFIC INSULIN SYRINGES MARKET, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 50.ASIA-PACIFIC INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 51.ASIA-PACIFIC INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 52.ASIA-PACIFIC INSULIN SYRINGES MARKET, BY END USER, 2020-2030($MILLION)
  • TABLE 53.JAPAN INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 54.JAPAN INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 55.JAPAN INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 56.CHINA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 57.CHINA INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 58.CHINA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 59.AUSTRALIA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 60.AUSTRALIAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 61.AUSTRALIA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 62.INDIA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 63.INDIAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 64.INDIA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 65.SOUTH KOREA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 66.SOUTH KOREAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 67.SOUTH KOREAINSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 68.REST OF ASIA-PACIFIC INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 69.REST OF ASIA-PACIFICINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 70.REST OF ASIA-PACIFIC INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 71.LAMEA INSULIN SYRINGES MARKET, BY COUNTRY, 2020-2030 ($MILLION)
  • TABLE 72.LAMEA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 73.LAMEA INSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 74.LAMEA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 75.BRAZIL INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 76.BRAZILINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 77.BRAZIL INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 78.SAUDI ARABIA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 79.SAUDI ARABIAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 80.SAUDI ARABIA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 81.SOUTH AFRICA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 82.SOUTH AFRICAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 83.SOUTH AFRICA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 84.REST OF LAMEA INSULIN SYRINGES MARKET, BY SYRINGE SIZE, 2020-2030 ($MILLION)
  • TABLE 85.REST OF LAMEAINSULIN SYRINGES MARKET, BY DISEASE, 2020-2030 ($MILLION)
  • TABLE 86.REST OF LAMEA INSULIN SYRINGES MARKET, BY END USER, 2020-2030 ($MILLION)
  • TABLE 01.ABBOTT: COMPANY SNAPSHOT
  • TABLE 02.ABBOTT: OPERATING SEGMENTS
  • TABLE 03.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 04.BIOCON: COMPANY SNAPSHOT
  • TABLE 05.BIOCON: OPERATING SEGMENTS
  • TABLE 06.BIOCON: PRODUCT PORTFOLIO
  • TABLE 07.BD: COMPANY SNAPSHOT
  • TABLE 08.BD: OPERATING SEGMENTS
  • TABLE 09.BD: PRODUCT PORTFOLIO
  • TABLE 10.CARDINAL HEALTH: COMPANY SNAPSHOT
  • TABLE 11.CARDINAL HEALTH: OPERATING SEGMENT
  • TABLE 12.CARDINAL HEALTH: PRODUCT PORTFOLIO
  • TABLE 13.ELI LILLY: COMPANY SNAPSHOT
  • TABLE 14.ELI LILLY: OPERATING SEGMENTS
  • TABLE 15.ELI LILLY: PRODUCT PORTFOLIO
  • TABLE 16.HMD: COMPANY SNAPSHOT
  • TABLE 17.HMD: OPERATING SEGMENTS
  • TABLE 18.HMD: PRODUCT PORTFOLIO:
  • TABLE 19.MEDLINE: COMPANY SNAPSHOT
  • TABLE 20.MEDLINE: OPERATING SEGMENTS
  • TABLE 21.MEDLINE: PRODUCT PORTFOLIO
  • TABLE 22.NIPRO: COMPANY SNAPSHOT
  • TABLE 23.NIPRO: OPERATING SEGMENTS
  • TABLE 24.NIPRO: PRODUCT PORTFOLIO:
  • TABLE 25.NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 26.NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 27.NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 28.TERUMO: COMPANY SNAPSHOT
  • TABLE 29.TERUMO CORPORATION: PRODUCT SEGMENTS
  • TABLE 30.TERUMO: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.INSULIN SYRINGES MARKET SEGMENTATION
  • FIGURE 02.TOP PLAYER POSITIONING, 2020
  • FIGURE 03.TOP INVESTMENT POCKETS
  • FIGURE 04.HIGH BARGAINING POWER OF SUPPLIER
  • FIGURE 05.MODERATEBARGAINING POWER OF BUYERS
  • FIGURE 06.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 07.HIGH INTENSITY OF RIVALRY
  • FIGURE 08.HIGH THREAT OF NEW ENTRANT
  • FIGURE 09.IMPACT ANALYSES, INSULIN SYRINGES MARKET
  • FIGURE 10.COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR 3/10 CC SYRINGES (0.3 ML), BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 11.COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR 1/2 CC SYRINGE (0.5 ML), BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 12.COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR 1CC SYRINGE (1 ML), BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 13.COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 14.COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR TYPE-1 DIABETES, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR TYPE-2 DIABETES, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR HOSPITALS, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 17.COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR HOMECARE SETTINGS, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 18.COMPARATIVE ANALYSIS OF INSULIN SYRINGES MARKET FOR OTHERS, BY COUNTRY, 2020 & 2030 (%)
  • FIGURE 01.ABBOTT: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 02.ABBOTT: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 03.ABBOTT: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 04.BIOCON: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 05.BIOCON: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 06.BIOCON: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 07.BD: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 08.BD: REVENUE SHARE BY SEGMENT, 2020 (%)
  • FIGURE 09.BD: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 10.CARDINAL HEALTH: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 11.CARDINAL HEALTH: REVENUE SHARE BY SEGMENT, 2019 (%)
  • FIGURE 12.CARDINAL HEALTH: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 13.NET SALES, 2018-2020 ($MILLION)
  • FIGURE 14.ELI LILLY REVENUE SHARE BY BUSINESS UNIT, 2020 (%)
  • FIGURE 15.ELI LILLY: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 16.NIPRO: NET SALES, 2018-2020 ($MILLION)
  • FIGURE 17.NIPRO: REVENUE SHARE BY SEGMENTS, 2020 (%)
  • FIGURE 18.NIPRO: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 19.NET SALES, 2018-2020 ($MILLION)
  • FIGURE 20.NOVO NORDISK: REVENUE SHARE BY REGION, 2020 (%)
  • FIGURE 21.NOVO NORDISK: REVENUE SHARE BY GEOGRAPHY, 2020 (%)
  • FIGURE 22.TERUMO: NET SALES, 2017-2019 ($MILLION)
  • FIGURE 23.TERUMO: REVENUE SHARE BY SEGMENTS, 2019 (%)
  • FIGURE 24.TERUMO: REVENUE SHARE BY REGION, 2019 (%)

The global insulin syringes was valued at $1,561.20 million in 2020, and is projected to reach $2,401.51 million by 2030, registering a CAGR of 4.4% from 2021 to 2030.

Insulin regulates fat and carbohydrate metabolism in the body. It is a peptide hormone, which is secreted in the pancreas by beta cells of the islets of Langerhans and it helps to regulate the glucose metabolism. It causes skeletal muscle cells and fat tissues to absorb glucose from the blood. An insulin syringe aids in delivering insulin to diabetic patients in required doses. The insulin syringes consist of three parts-a needles, a barrel, and a plunger, and is available in various sizes such as 3/10 cc Syringe, 1/ 2 cc Syringe and 1cc syringe.

The major factor that contributes to the growth of the insulin syringes market include surge in aging population and increasing number of diabetic patients globally. Furthermore, other factors such as favorable government policies related to insulin syringes and are the key factors drives the growth of the market. In addition, increase in incidence of obesity and people adopting an unhealthy lifestyle supplement the growth of market. However, alternative modes of insulin delivery and high price of insulin restrict market growth. Conversely, rise in healthcare spending on diabetes across the world and growing awareness related to insulin syringes in developing economies is expected to offer lucrative opportunities during the forecast period.

The insulin syringes market size is studied on the basis of syringe size, disease type end user and region to provide a detailed assessment of the market. On the basis of syringe size, it is bifurcated into 3/10 cc Syringe (0.3ml), 1/ 2 cc Syringe (0.5ml) 1cc syringe (1ml) and others. On the basis of disease type, it is bifurcated into type -1 diabetes and type-2 diabetes. By end user, it is bifurcated into hospital & clinics, homecare setting, and others. by region the market is bifurcated into North America, Europe, Asia-Pacific and LAMEA.

The report provides a comprehensive analysis of the leading companies operating in the global market such as Novo Nordisk A/S, Biocon Ltd Abbott Laboratories, Terumo Corporation, Cardinal Health Inc, Beckton and Dickinson Company, Eli Lilly and Company, Nipro Medical Corporation, Medline Industries and Hindustan syringe and medical device ltd.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
  • It offers a quantitative analysis from 2020 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
  • A comprehensive analysis of four regions is provided to determine the existing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global insulin syringes market.

KEY MARKET SEGMENTS

By Syringe Size

  • 3/10 CC Syringe (0.3ml)
  • 1/2 CC Syringe (0.5ml)
  • 1CC Syringe (1ml)
  • Others

By Disease

  • Type 1 Diabetes
  • Type 2 Diabetes)

By End User

  • Hospitals & Clinics
  • Homecare Settings
  • Others)

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • South Africa
  • Saudi Arabia
  • Rest of LAMEA

KEY MARKET PLAYERS

  • Novo Nordisk A/S
  • Biocon Ltd
  • Abbott Laboratories
  • Terumo Corporation
  • Cardinal Health Inc
  • Beckton and Dickinson Company
  • Eli Lilly and Company
  • Nipro Medical Corporation
  • Medline Industries
  • Hindustan syringe and medical device Ltd ..

LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)

  • Medtronic Plc.
  • Sanofi S.A
  • B.Braun Melunsung
  • F.Hoffman La.Roche

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Research methodology
    • 1.3.1.Primary research
    • 1.3.2.Secondary research
    • 1.3.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.3.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Top player positioning
    • 3.2.1.Top investment pockets
  • 3.3.Key forces shaping insulin syringes industry/market
  • 3.4.Market dynamics
      • 3.4.1.1.Rise in prevalence of Diabetes
      • 3.4.1.2.Surge in healthcare expenditure
      • 3.4.1.3.Surge in geriatric population
    • 3.4.2.Restraints
      • 3.4.2.1.High price of Insulin
      • 3.4.2.2.Availability of alternative modes of insulin delivery
    • 3.4.3.Opportunity
      • 3.4.3.1.High growth potential in Developing Countries
    • 3.4.4.Impact Analysis
  • 3.5.Impact of Covid-19 on the market

CHAPTER 4:INSULIN SYRINGES MARKET, BY SYRINGE SIZE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.3/10 cc syringe (0.3ml)
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast
    • 4.2.3.Market analysis, by country
  • 4.3.1/2 cc Syringe (0.5 ml)
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.1cc Syringe (1 ml)
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country
  • 4.5.Others
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast
    • 4.5.3.Market analysis, by country

CHAPTER 5:INSULIN SYRINGES MARKET, BY DISEASE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Type-1 Diabetes
    • 5.2.1.Market analysis, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Type-2 Diabetes
    • 5.3.1.Market size and forecast
    • 5.3.2.Market analysis, by country

CHAPTER 6:INSULIN SYRINGES MARKET, BY END USER

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Hospitals& Clinics
    • 6.2.1.Market size and forecast
    • 6.2.2.Market analysis, by country
  • 6.3.Homecare Settings
    • 6.3.1.Market size and forecast
    • 6.3.2.Market analysis, by country
  • 6.4.Others.
    • 6.4.1.Market size and forecast
    • 6.4.2.Market analysis, by country

CHAPTER 7:INSULIN SYRINGES MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trendsand opportunities
    • 7.2.2.Market size and forecast, by country
    • 7.2.3.Market size and forecast, by Syringe Size
    • 7.2.4.Market size and forecast, by Disease
    • 7.2.5.Market size and forecast, by end user
    • 7.2.6.U.S.
      • 7.2.6.1.U.S. Market size and forecast, by Syringe Size
      • 7.2.6.2.U.S. Market size and forecast, by disease
      • 7.2.6.3.U.S. Market size and forecast, by end user
    • 7.2.7.Canada
      • 7.2.7.1.Canada. Market size and forecast, by syringe size
      • 7.2.7.2.Canada. Market size and forecast, by disease
      • 7.2.7.3.Canada Market size and forecast, by end user
    • 7.2.8.Mexico
      • 7.2.8.1.Mexico Market size and forecast, by Syringe Size
      • 7.2.8.2.Mexico. Market size and forecast, by disease
      • 7.2.8.3.Mexico Market size and forecast, by end user
  • 7.3.Europe
    • 7.3.1.Key market trends and opportunities
    • 7.3.2.Market size and forecast, by country
    • 7.3.3.Market size and forecast, by Syringe Size
    • 7.3.4.Market size and forecast, by Disease
    • 7.3.5.Market size and forecast, by end user
    • 7.3.6.Germany
      • 7.3.6.1.Germany Market size and forecast, by syringe Size
      • 7.3.6.2.Germany Market size and forecast, by disease
      • 7.3.6.3.Germany Market size and forecast, by end user
    • 7.3.7.France
      • 7.3.7.1.France Market size and forecast, by Syringe Size
      • 7.3.7.2.France Market size and forecast, by disease
      • 7.3.7.3.France Market size and forecast, by end user
    • 7.3.8.UK
      • 7.3.8.1.UK Market size and forecast, by Syringe Size
      • 7.3.8.2.UK Market size and forecast, by disease
      • 7.3.8.3.UK Market size and forecast, by end user
    • 7.3.9.Italy
      • 7.3.9.1.Italy Market size and forecast, by Syringe Size
      • 7.3.9.2.Italy Market size and forecast, by disease
      • 7.3.9.3.Italy Market size and forecast, by end user
    • 7.3.10.Spain
      • 7.3.10.1.Spain Market size and forecast, by Syringe Size
      • 7.3.10.2.Spain Market size and forecast, by disease
      • 7.3.10.3.Spain Market size and forecast, by end user
    • 7.3.11.Rest of Europe
      • 7.3.11.1.Rest of Europe Market size and forecast, by Syringe Size
      • 7.3.11.2.Rest of Europe Market size and forecast, by disease
      • 7.3.11.3.Rest of Europe Market size and forecast, by end user
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trendsand opportunities
    • 7.4.2.Market size and forecast, by country
    • 7.4.3.Market size and forecast, by Syringe Size
    • 7.4.4.Market size and forecast, by disease
    • 7.4.5.Market size and forecast, by end user
    • 7.4.6.Japan
      • 7.4.6.1.Japan Market size and forecast, by syringe Size
      • 7.4.6.2.Japan Market size and forecast, by disease
      • 7.4.6.3.Japan Market size and forecast, by end user
    • 7.4.7.China
      • 7.4.7.1.China Market size and forecast, by syringe Size
      • 7.4.7.2.China Market size and forecast, by Disease
      • 7.4.7.3.China Market size and forecast, by end user
    • 7.4.8.Australia
      • 7.4.8.1.Australia Market size and forecast, by Syringe Size
      • 7.4.8.2.Australia Market size and forecast, by Disease
      • 7.4.8.3.Australia Market size and forecast, by end user
    • 7.4.9.India
      • 7.4.9.1.India Market size and forecast, by Syringe Size
      • 7.4.9.2.India Market size and forecast, by Disease
      • 7.4.9.3.India Market size and forecast, by end user
    • 7.4.10.South Korea
      • 7.4.10.1.South Korea Market size and forecast, by Syringe Size
      • 7.4.10.2.South Korea Market size and forecast, by Disease
      • 7.4.10.3.South Korea Market size and forecast, by end user
    • 7.4.11.Rest of Asia-Pacific
      • 7.4.11.1.Rest of Asia-Pacific Market size and forecast, by Syringe Size
      • 7.4.11.2.Rest of Asia-Pacific Market size and forecast, by disease
      • 7.4.11.3.Rest of Asia-Pacific Market size and forecast, by end user
  • 7.5.LAMEA
    • 7.5.1.Key market trendsand opportunities
    • 7.5.2.Market size and forecast, by country
    • 7.5.3.Market size and forecast, by Syringe Size
    • 7.5.4.Market size and forecast, by disease
    • 7.5.5.Market size and forecast, by end user
    • 7.5.6.Brazil
      • 7.5.6.1.Brazil Market size and forecast, by age group
      • 7.5.6.2.Brazil Market size and forecast, by disease
      • 7.5.6.3.Brazil Market size and forecast, by end user
    • 7.5.7.Saudi Arabia
      • 7.5.7.1.Saudi Arabia Market size and forecast, by Syringe Size
      • 7.5.7.2.Saudi Arabia Market size and forecast, by Disease
      • 7.5.7.3.Saudi Arabia Market size and forecast, by end user
    • 7.5.8.South Africa
      • 7.5.8.1.South Africa Market size and forecast, by Syringe Size
      • 7.5.8.2.South Africa Market size and forecast, by Disease
      • 7.5.8.3.South Africa Market size and forecast, by end user
    • 7.5.9.Rest of LAMEA
      • 7.5.9.1.Rest of LAMEA Market size and forecast, by Syringe Size
      • 7.5.9.2.Rest of LAMEA Market size and forecast, by disease
      • 7.5.9.3.Rest of LAMEA Market size and forecast, by end user

CHAPTER 8:COMPANY PROFILES

  • 8.1.Abbott Laboratories
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.Biocon Ltd
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Product portfolio
    • 8.2.5.Business performance
  • 8.3.Becton, Dickinson and Company
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.CARDINAL HEALTH
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
  • 8.5.Eli Lily and Company
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Product portfolio
    • 8.5.5.Business performance
  • 8.6.HINDUSTAN SYRINGES AND MEDICAL DEVICES LTD
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Product portfolio
  • 8.7.Medline Industries
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
  • 8.8.NIPRO MEDICAL CORPORATION
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
  • 8.9.NOVO NORDISk
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
  • 8.10.TERUMO CORPORATION
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance
Back to Top
전화 문의
F A Q